Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma
DRUG: Pembrolizumab|DRUG: Axitinib
Recruitment Rate Feasibility, Measured as the percentage of eligible patients with a \>20% tumor response who consent to participate in the adaptive therapy.

Successful enrollment if at least 70% of eligible patients agree to participate in the adaptive therapy, Up to 36 Months|Progression Free Survival (PFS), Measured from the start of treatment until the point of disease progression or death from any cause., Up to 12 Months
Persistent Disease Control, Measured as the proportion of patients who complete adaptive therapy and do not requiring disease re-initiation for more than 12 months after therapy discontinuation., Up to 36 Months|Overall Survival (OS), Measured as time from date of enrollment to death from any cause., Up to 36 Months
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).